304 related articles for article (PubMed ID: 34262941)
61. Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients.
Wang W; Zhang C; Yu Q; Zheng X; Yin C; Yan X; Liu G; Song Z
BMC Gastroenterol; 2021 Feb; 21(1):68. PubMed ID: 33579192
[TBL] [Abstract][Full Text] [Related]
62. Genomic Instability of Mutation-Derived Gene Prognostic Signatures for Hepatocellular Carcinoma.
Song ZB; Yu Y; Zhang GP; Li SQ
Front Cell Dev Biol; 2021; 9():728574. PubMed ID: 34676211
[TBL] [Abstract][Full Text] [Related]
63. Identification and validation of ferroptosis-associated gene-based on immune score as prognosis markers for hepatocellular carcinoma patients.
Wang J; Han K; Zhang C; Chen X; Li Y; Zhu L; Luo T
J Gastrointest Oncol; 2021 Oct; 12(5):2345-2360. PubMed ID: 34790397
[TBL] [Abstract][Full Text] [Related]
64. Development and Verification of an Immune-Related Gene Pairs Prognostic Signature in Hepatocellular Carcinoma.
Feng X; Mu S; Ma Y; Wang W
Front Mol Biosci; 2021; 8():715728. PubMed ID: 34660693
[TBL] [Abstract][Full Text] [Related]
65. Pyroptosis-Related Risk Signature Exhibits Distinct Prognostic, Immune, and Therapeutic Landscapes in Hepatocellular Carcinoma.
Zhao Y; Song Q; Xu F; Zhou Y; Zuo X; Zhang Z
Front Genet; 2022; 13():823443. PubMed ID: 35368686
[No Abstract] [Full Text] [Related]
66. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma.
Sun XY; Yu SZ; Zhang HP; Li J; Guo WZ; Zhang SJ
Cancer Med; 2020 Apr; 9(8):2868-2878. PubMed ID: 32068352
[TBL] [Abstract][Full Text] [Related]
67. Construction and Validation of an Immune Cell Signature Score to Evaluate Prognosis and Therapeutic Efficacy in Hepatocellular Carcinoma.
Xu L; Jian X; Liu Z; Zhao J; Zhang S; Lin Y; Xie L
Front Genet; 2021; 12():741226. PubMed ID: 34646307
[No Abstract] [Full Text] [Related]
68. Construction of a prognostic model based on nine immune-related genes and identification of small molecule drugs for hepatocellular carcinoma (HCC).
Zhang J; Chen G; Zhang J; Zhang P; Ye Y
Am J Transl Res; 2020; 12(9):5108-5130. PubMed ID: 33042409
[TBL] [Abstract][Full Text] [Related]
69. Development of a Toll-Like Receptor-Based Gene Signature That Can Predict Prognosis, Tumor Microenvironment, and Chemotherapy Response for Hepatocellular Carcinoma.
Liu L; Liu B; Yu J; Zhang D; Shi J; Liang P
Front Mol Biosci; 2021; 8():729789. PubMed ID: 34621787
[No Abstract] [Full Text] [Related]
70. Identification and Validation of a Prognostic lncRNA Signature for Hepatocellular Carcinoma.
Li W; Chen QF; Huang T; Wu P; Shen L; Huang ZL
Front Oncol; 2020; 10():780. PubMed ID: 32587825
[No Abstract] [Full Text] [Related]
71. A novel immune checkpoint-related gene signature for hepatocellular carcinoma to predict clinical outcomes and therapeutic response.
Tian S; Hu Y; Yang C; Yu J; Liu J; Xuan G; Liu Y; Sun K; Zhang M; Ma S; Shang Y; Zhou X; Han Y
Math Biosci Eng; 2022 Mar; 19(5):4719-4736. PubMed ID: 35430837
[TBL] [Abstract][Full Text] [Related]
72. Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma.
Huo J; Wu L; Zang Y; Dong H; Liu X; He F; Zhang X
BMC Cancer; 2021 Jan; 21(1):31. PubMed ID: 33413205
[TBL] [Abstract][Full Text] [Related]
73. Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients.
Fei H; Chen X
Am J Cancer Res; 2022; 12(5):2337-2349. PubMed ID: 35693084
[TBL] [Abstract][Full Text] [Related]
74. A novel prognostic model based on single-cell RNA sequencing data for hepatocellular carcinoma.
Lu J; Chen Y; Zhang X; Guo J; Xu K; Li L
Cancer Cell Int; 2022 Jan; 22(1):38. PubMed ID: 35078458
[TBL] [Abstract][Full Text] [Related]
75. Development and validation of a survival model based on autophagy-associated genes for predicting prognosis of hepatocellular carcinoma.
Yang W; Niu L; Zhao X; Duan L; Li Y; Wang X; Zhang Y; Zhou W; Liu J; Zhao Q; Han Y; Fan D; Hong L
Am J Transl Res; 2020; 12(10):6705-6722. PubMed ID: 33194067
[TBL] [Abstract][Full Text] [Related]
76. Differentially expressed liver exosome-related genes as candidate prognostic biomarkers for hepatocellular carcinoma.
Zuo B; Kuai J; Long J; Bian J; Yang X; Yang X; Xun Z; Li Y; Sun H; Sang X; Zhao H
Ann Transl Med; 2022 Aug; 10(15):817. PubMed ID: 36034976
[TBL] [Abstract][Full Text] [Related]
77. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
78. A Novel Gene Signature Associated with Inflammatory Responses and Immune Status Assists in Prognosis and Intervention for Patients with HCC.
Lu G; Du R; Feng B; Wang J; Zhang F; Pei J; Wang Y; Shang Y
J Inflamm Res; 2022; 15():6729-6743. PubMed ID: 36536645
[TBL] [Abstract][Full Text] [Related]
79. Identification of Gene Signatures for Diagnosis and Prognosis of Hepatocellular Carcinomas Patients at Early Stage.
Gan X; Luo Y; Dai G; Lin J; Liu X; Zhang X; Li A
Front Genet; 2020; 11():857. PubMed ID: 32849835
[TBL] [Abstract][Full Text] [Related]
80. Promising key genes associated with tumor microenvironments and prognosis of hepatocellular carcinoma.
Pan L; Fang J; Chen MY; Zhai ST; Zhang B; Jiang ZY; Juengpanich S; Wang YF; Cai XJ
World J Gastroenterol; 2020 Feb; 26(8):789-803. PubMed ID: 32148377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
